日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

High-purity CTC RNA sequencing identifies prostate cancer lineage phenotypes prognostic for clinical outcomes

高纯度循环肿瘤细胞RNA测序可识别前列腺癌谱系表型,这些表型可预测临床结果。

Marina N Sharifi ,Jamie M Sperger ,Amy K Taylor ,Katharine E Tippins ,Shannon R Reese ,Viridiana Carreno ,Katherine R Kaufmann ,Alex H Chang ,Luke A Nunamaker ,Charlotte Linebarger ,Leilani Mora-Rodriguez ,Jennifer L Schehr ,Hannah M Krause ,Kyle T Helzer ,Matthew L Bootsma ,Grace C Blitzer ,John M Floberg ,Christos E Kyriakopoulos ,Hamid Emamekhoo ,Elisabeth I Heath ,Meghan Wells ,Scott T Tagawa ,Martin Sjöström ,Atish D Choudhury ,Menggang Yu ,Andrew J Armstrong ,Dana E Rathkopf ,Himisha Beltran ,Peter S Nelson ,Felix Y Feng ,Scott M Dehm ,David Kosoff ,Xiao X Wei ,Rana R McKay ,Shuang G Zhao ,Joshua M Lang

Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma

BCMA CAR-T细胞疗法治疗复发/难治性多发性骨髓瘤患者的长期随访

Chunxiang Jin ,Rongrong Chen ,Shan Fu ,Mingming Zhang ,Yuanyin Teng ,Tingting Yang ,Fengmei Song ,Jingjing Feng ,Ruimin Hong ,Jiazhen Cui ,Simao Huang ,Huijun Xu ,Yanlei Zhang ,Guoqing Wei ,Zhen Cai ,Yok-Lam Kwong ,Thomas Sau Yan Chan ,Alex H Chang ,He Huang ,Yongxian Hu

Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia

CD19 和 CD22 CAR-T 疗法序贯治疗复发/难治性成人 B 细胞急性淋巴细胞白血病显示出显著疗效和良好的安全性

Tingting Yang # ,Yetian Dong # ,Mingming Zhang ,Jingjing Feng ,Shan Fu ,Pingnan Xiao ,Ruimin Hong ,Huijun Xu ,Jiazhen Cui ,Simao Huang ,Guoqing Wei ,Delin Kong ,Jia Geng ,Alex H Chang ,He Huang ,Yongxian Hu

CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies

在血液系统恶性肿瘤中,CAR-T细胞疗法相关的细胞因子释放综合征和治疗反应受肠道微生物群的调节。

Yongxian Hu # ,Jingjing Li # ,Fang Ni # ,Zhongli Yang # ,Xiaohua Gui ,Zhiwei Bao ,Houli Zhao ,Guoqing Wei ,Yiyun Wang ,Mingming Zhang ,Ruimin Hong ,Linqin Wang ,Wenjun Wu ,Mohamad Mohty ,Arnon Nagler ,Alex H Chang ,Marcel R M van den Brink ,Ming D Li ,He Huang

CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study

CD19/CD22 双靶向 CAR-T 细胞疗法治疗复发/难治性侵袭性 B 细胞淋巴瘤:安全性和有效性研究

Guoqing Wei #, Yanlei Zhang #, Houli Zhao #, Yiyun Wang, Yandan Liu, Bin Liang, Xiujian Wang, Huijun Xu, Jiazhen Cui, Wenjun Wu, Kui Zhao, Arnon Nagler, Alex H Chang, Yongxian Hu, He Huang

Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy

鲁索替尼可减轻 CAR-T 疗法期间的类固醇难治性 CRS

Jing Pan ,Biping Deng ,Zhuojun Ling ,Weiliang Song ,Jinlong Xu ,Jiajia Duan ,Zelin Wang ,Alex H Chang ,Xiaoming Feng ,Yue Tan

Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse

嵌合抗原受体 T 细胞治疗移植后复发急性淋巴细胞白血病的疗效和安全性

Lijuan Ding, Yiyun Wang, Ruimin Hong, Houli Zhao, Linghui Zhou, Guoqing Wei, Wenjun Wu, Huijun Xu, Yanlei Zhang, Yi Luo, Jimin Shi, Alex H Chang, Yongxian Hu, He Huang

Overexpression of CXCR7 accelerates tumor growth and metastasis of lung cancer cells

CXCR7过度表达加速肺癌细胞的肿瘤生长和转移

Huan Liu, Qian Cheng, Dong-Sheng Xu, Wen Wang, Zheng Fang, Dong-Dong Xue, Ya Zheng, Alex H Chang, Yan-Jun Lei

Chimeric Antigen Receptor-Modified T Cells Redirected to EphA2 for the Immunotherapy of Non-Small Cell Lung Cancer

嵌合抗原受体修饰的T细胞重定向至EphA2用于非小细胞肺癌的免疫治疗

Ning Li, Shaohui Liu, Mingjiao Sun, Wei Chen, Xiaogang Xu, Zhu Zeng, Yemin Tang, Yongquan Dong, Alex H Chang, Qiong Zhao0